Dapagliflozin for Cystinuria

Phase-Based Estimates
1
Effectiveness
2
Safety
University of California, San Francisco, San Francisco, CA
Cystinuria
Dapagliflozin - Drug
Eligibility
18+
All Sexes
Eligible conditions
Cystinuria

Study Summary

The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study

See full description

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Dapagliflozin will improve 1 primary outcome in patients with Cystinuria. Measurement will happen over the course of Samples collected at Initial visit and Day 7 visit, preserved and stored; mass spectometry analysis done over the course of 6 months.

Month 6
Change in cysteine level in freshly voided urine

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Side Effects for

Dapagliflozin
Cervicovaginal infection
20%
Urinary tract infections
13%
This histogram enumerates side effects from a completed 2018 Phase 4 trial (NCT03006471) in the Dapagliflozin ARM group. Side effects include: Cervicovaginal infection with 20%, Urinary tract infections with 13%.

Trial Design

2 Treatment Groups

Control
Study Drug

This trial requires 10 total participants across 2 different treatment groups

This trial involves 2 different treatments. Dapagliflozin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Study Drug
Drug
The study drug Dapagliflozin
ControlNo treatment in the control group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dapagliflozin
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: samples collected at initial visit and day 7 visit, preserved and stored; mass spectometry analysis done over the course of 6 months
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly samples collected at initial visit and day 7 visit, preserved and stored; mass spectometry analysis done over the course of 6 months for reporting.

Closest Location

University of California, San Francisco - San Francisco, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Individuals with a history of cystine kidney stones are at an increased risk of developing another stone show original
able and willing to provide consent
Adults aged 18 or older, both male and female. show original
The person had cystinuria documented on a prior 24-hour urine collection and/or stone analysis. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can cystinuria be cured?

Add answer

The data suggest that renal cystinosis can be cured for at least 1 year after the termination of treatment. Patients should be instructed about the recurrence of cystinosis during follow-up visits.

Unverified Answer

What are common treatments for cystinuria?

Add answer

Although not a cure, an individual with cystinuria may avoid most complications with a low-ysine diet and can minimize the impact of the disease by eliminating the risk factors for worsening the disease. Therefore, management of this disease should start with eliminating the risk factors early.

Unverified Answer

How many people get cystinuria a year in the United States?

Add answer

About 1,100,000 Caucasian children in the United States in ages 5-19 (9.4% of population; 9.1% of men and 10% of women) may have Cystinuria, making them the third-most prevalent urological cause in this demographic. This finding does not take into account the prevalence of cystinuria in the elderly population (10% of males and 15% of females in age 65 and above). These studies are limited by the absence of cystinuria data in all states, and by the use of only laboratory tests to diagnose cystinuria. The prevalence of cystinuria in adult population seems uncertain.

Unverified Answer

What causes cystinuria?

Add answer

Inherited risk of developing cystinuria has been demonstrated and may be due to a combination of genetic and environmental factors. We hypothesize that cystinuria has a genetically determined defect of the proximal tubule of the nephron. We suggest a multifactorial approach to cystinuria treatment and emphasize that pharmacological treatments are not necessarily required.

Unverified Answer

What are the signs of cystinuria?

Add answer

All children with unexplained developmental delay or motor skill disturbance should be questioned, including about urination problems, appetite impairment, or weight loss. Cystinuria should be suspected if the serum cystine level is less than the upper limit of the reference range, and this can be confirmed by the urine cystine-to- creatinine ratio. Children with cystinuria commonly present with developmental delay, but children with autosomal recessive cystinosis commonly present with symptoms of nephrocalcinosis and Fanconi's syndrome.

Unverified Answer

What is cystinuria?

Add answer

The major diagnostic criterion for cystinuria remains the demonstration of high urinary cystine levels (≥ 75 μmol/min). However, these levels could be missed in about 20% of cases. There is now a test (Diaz's cystine test) that shows an excellent diagnostic performance, even in those cases with borderline values. Cystinuria is an almost exclusively renal condition and should be considered only when the symptoms and the signs of deterioration are present.

Unverified Answer

How does dapagliflozin work?

Add answer

Findings from a recent study suggest that the pharmacokinetics of dapagliflozin are influenced by CYP2C19 phenotype; a minor allele of CYP2C19 can lead to increased exposure to dapagliflozin. Because the pharmacokinetics and efficacy profile of dapagliflozin is maintained across CYP2C19 phenotypes, it appears to have no significant effect on clinical efficacy.

Unverified Answer

Who should consider clinical trials for cystinuria?

Add answer

Clinical trials can play a role in determining treatments for Cystinuria but only by conducting clinical trials and reporting outcomes can Cystinuria be truly understood. Clinical trials can help patients to determine the best treatment regimen that will help minimize their symptoms but will help with the treatment of Cystinuria in general.

Unverified Answer

Is dapagliflozin safe for people?

Add answer

Dapagliflozin is safe for women who are pregnant, breastfeeding, have kidney disease or on other DM medications. For people not on DM medications and those who are not pregnant, no firm evidence of increased risk has been found. For people taking other DM medications, risks have not been established. For women taking dapagliflozin, kidney function should be checked regularly with a test that measures urinary albumin excretion. Women who have polycystic ovary syndrome (PCOS) should not take dapagliflozin but rather other options [such as metformin or metformin/gliflozin].

Unverified Answer

What are the common side effects of dapagliflozin?

Add answer

The most commonly occurring non-serious adverse events include constipation, headache, fatigue, vomiting, and a rash. The magnitude of these effects was generally mild to moderate, and no deaths or serious adverse events were reported.

Unverified Answer

What is the latest research for cystinuria?

Add answer

There have been a small number of reports regarding CYSU in the last few years, but their overall findings have not influenced treatment; thus, there is no necessity to change treatment. Additional studies are warranted.

Unverified Answer

Is dapagliflozin typically used in combination with any other treatments?

Add answer

The vast majority of patients who are receiving DAP and concomitant CYP3A inhibitors are not receiving additional treatment. A minority of patients are being treated with one or more additional antidiabetes medications. The concurrent use of CYP3A inhibitors with DAP may have pharmacodynamic or pharmacokinetic implications if not carefully evaluated, which deserves further analysis.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Cystinuria by sharing your contact details with the study coordinator.